Recent Advances in Functionalized Nanoparticles in Cancer Theranostics
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Cancer theranostics is the combination of diagnosis and therapeutic approaches for cancer, which is essential in personalized cancer treatment. The aims of the theranostics application of nanoparticles in cancer detection and therapy are to reduce delays in treatment and hence improve patient care. Recently, it has been found that the functionalization of nanoparticles can improve the efficiency, performance, specificity and sensitivity of the structure, and increase stability in the body and acidic environment. Moreover, functionalized nanoparticles have been found to possess a remarkable theranostic ability and have revolutionized cancer treatment. Each cancer treatment modality, such as MRI-guided gene therapy, MRI-guided thermal therapy, magnetic hyperthermia treatment, MRI-guided chemotherapy, immunotherapy, photothermal and photodynamic therapy, has its strengths and weaknesses, and combining modalities allows for a better platform for improved cancer control. This is why cancer theranostics have been investigated thoroughly in recent years and enabled by functionalized nanoparticles. In this topical review, we look at the recent advances in cancer theranostics using functionalized nanoparticles. Through understanding and updating the development of nanoparticle-based cancer theranostics, we find out the future challenges and perspectives in this novel type of cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164 · cited 1×
“Now, functionalized NPs overcome those shortcomings and can also act as a contrast agent for diagnosis in therapeutic applications [89].”
BackgroundBunney, P. E., Zink, A. N., Holm, A. A., Billington, C. J., & Kotz, C. M. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.03.040 · Cited by 2,104
The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular Interaction
Hoshyar, N., Gray, S., Han, H., & Bao, G. (2016) · Nanomedicine · doi:10.2217/nnm.16.5 · Cited by 1,990 · cited 1×
“A nanoscaled material’s size, shape surface chemistry and structure allow their functionalization and utilization in theranostic applications [82].”
BackgroundIron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications
Dadfar, S. M., Roemhild, K., Drude, N. I., von Stillfried, S., Knüchel, R., Kiessling, F., & Lammers, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.005 · Cited by 1,181
Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer
Singh, P., Pandit, S., Mokkapati, V. R. S. S., Garg, A., Ravikumar, V., & Mijakovic, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071979 · Cited by 1,038
Wu, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080771 · Cited by 1,030 · cited 1×
“EPR is a universal pathophysiological phenomenon and mechanism where macromolecules with certain sizes above 40 kDa can progressively accumulate in the tumour vascularized area and achieve targeted delivery and retention of the anticancer compound into the solid tumour [10].”
BackgroundWirth, T., Parker, N., & Ylä-Herttuala, S. (2013) · Gene · doi:10.1016/j.gene.2013.03.137 · Cited by 607
FOXO3: A Major Gene for Human Longevity - A Mini-Review
Morris, B. J., Willcox, D. C., Donlon, T. A., & Willcox, B. J. (2015) · Gerontology · doi:10.1159/000375235 · Cited by 353
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
Araujo, J., & Logothetis, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.015 · Cited by 244
Cited by
Recent Advances in Surface Functionalization of Magnetic Nanoparticles
Comanescu, C. (2023) · Coatings · doi:10.3390/coatings13101772 · Cited by 132
Famta, P., Shah, S., Vambhurkar, G., Pandey, G., Bagasariya, D., Kumar, K. C., Prasad, S. B., Shinde, A., Wagh, S., Srinivasarao, D. A., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01669-9 · Cited by 21
Sharma, S., Bhattacharya, S., Joshi, K., & Singh, S. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05331-8 · Cited by 13
Gálvez-Rodríguez, A., Ferino-Pérez, A., Rodríguez-Riera, Z., Guerra, I. R., & Jáuregui-Haza, U. J. (2023) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2023.108569 · Cited by 2
Metadata
- Authors
- Siddique, S., & Chow, J. C. L.
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2022-08-17
- Volume
- 12
- Issue
- 16
- Pages
- 2826
- ISSN
- 2079-4991 (ISSN-L)
- OpenAlex
- W4293065232
- Cited by
- 139
- References
- 10
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances in Functionalized Nanoparticles in Cancer Theranostics. https://app.cochat.ai/papers/10.3390/nano12162826
- The paper
- Siddique, S., & Chow, J. C. L. (2022). Recent Advances in Functionalized Nanoparticles in Cancer Theranostics. Nanomaterials. https://doi.org/10.3390/nano12162826
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.